PD-L1 High Expression (TPS >= 50%)

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

121 sites for NCT04660344

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Infiltrating Bladder Urothelial Carcinoma

atezolizumab

immunotherapy

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

116 sites for NCT04740918

ERBB2 Amplification, +7 more biomarkers

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

207 sites for NCT04513925

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

161 sites for NCT04746924

PD-L1 High Expression (TPS >= 50%)

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

ociperlimab, +1 more drug

immunotherapy

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

51 sites for NCT04665843

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Head and Neck Squamous Cell Carcinoma

atezolizumab, +1 more drug

immunotherapy

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

67 sites for NCT04262856

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

domvanalimab, +2 more drugs

immunotherapy